Lupin appoints Alok Sonig as CEO, US generics and global head, generics R&D and biosimilars

Lupin Limited has appointed Alok Sonig as CEO – US generics and global head – generics R&D and biosimilars. Alok will lead and have overall responsibility for the US generics business including R&D in India and USA and the commercial side of the business in USA. He will also be responsible for Lupin’s global biosimilars business. With over 23 years of experience in the industry, Alok brings an established track record of success in the pharmaceutical and healthcare sectors to Lupin.

Most recently, Alok was CEO of developed markets (US, Canada, Europe, and Japan) at Dr Reddy’s. Prior to Dr Reddy’s, Alok spent nearly 15 years at Bristol-Myers Squibb, where he held several positions of increasing responsibilities in general management, country leadership roles, global strategy, and marketing.